[{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2025-02-25T14:41:39.851Z","phase":"Phase 1","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 01/14/2025","primary_completion_date":" 01/14/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-14"},{"id":"cf9f2b4a-201f-4caa-8789-84fd3a614f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554341","created_at":"2023-06-18T20:08:30.389Z","updated_at":"2024-07-02T16:34:27.622Z","phase":"Phase 2","brief_title":"Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-10"},{"id":"f0120f59-10df-43f7-b5bb-987a4f3afad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493215","created_at":"2022-08-09T17:04:45.434Z","updated_at":"2024-07-02T16:35:12.164Z","phase":"Phase 2","brief_title":"Imatinib TDM in GIST","source_id_and_acronym":"NCT05493215","lead_sponsor":"Reema A. Patel","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-01"},{"id":"3b472c71-761b-4c06-a89b-3a6142cd7c02","acronym":"AVIATOR2020","url":"https://clinicaltrials.gov/study/NCT04927260","created_at":"2021-06-15T17:53:23.444Z","updated_at":"2024-07-02T16:35:25.233Z","phase":"","brief_title":"French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients","source_id_and_acronym":"NCT04927260 - AVIATOR2020","lead_sponsor":"Centre Leon Berard","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-25"},{"id":"beae3831-e867-4796-98b5-a4cab6099ed8","acronym":"NAVIGATOR","url":"https://clinicaltrials.gov/study/NCT02508532","created_at":"2021-01-17T17:33:18.563Z","updated_at":"2024-07-02T16:36:08.544Z","phase":"Phase 1","brief_title":"(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors","source_id_and_acronym":"NCT02508532 - NAVIGATOR","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 03/06/2020","primary_completion_date":" 03/06/2020","study_txt":" Completion: 06/03/2021","study_completion_date":" 06/03/2021","last_update_posted":"2022-06-21"},{"id":"ec0044ab-0bc9-4c5a-8f2a-82680d79f10c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02847429","created_at":"2021-01-18T13:58:42.892Z","updated_at":"2024-07-02T16:36:35.764Z","phase":"Phase 3","brief_title":"Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST","source_id_and_acronym":"NCT02847429","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-01-22"},{"id":"28db9516-1c03-4c8b-98d1-37ee5af86d30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03862885","created_at":"2021-01-18T19:03:16.863Z","updated_at":"2024-07-02T16:36:42.722Z","phase":"","brief_title":"Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST","source_id_and_acronym":"NCT03862885","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"},{"id":"8aebf424-8909-4895-a7e6-e2f46f58b8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02642016","created_at":"2021-01-18T12:51:11.933Z","updated_at":"2024-07-02T16:36:58.921Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02642016","lead_sponsor":"Celldex Therapeutics","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT positive • PDGFRA D842V • KIT expression","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive • PDGFRA D842V • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-0158"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/30/2018","primary_completion_date":" 01/30/2018","study_txt":" Completion: 06/04/2019","study_completion_date":" 06/04/2019","last_update_posted":"2019-06-12"},{"id":"4ed8fa9f-6144-4f0c-b60f-f530e4d76c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243346","created_at":"2021-01-17T17:54:43.344Z","updated_at":"2024-07-02T16:37:09.392Z","phase":"Phase 2","brief_title":"Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene","source_id_and_acronym":"NCT01243346","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2018-06-28"}]